ArticleBMC health services research2014
Multiple sclerosis in Germany: data analysis of administrative prevalence and healthcare delivery in the statutory health system.
Article in BMC health services research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Systematic literature review and meta-analysis of the prevalence of secondary progressive multiple sclerosis in the USA, Europe, Canada, Australia, and Brazil.BMC neurology · 2022Pooled it
- Complex intervention for MS patients in Germany - can it be cost-saving for the society?The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Disparities in patient share and characteristics between disease-modifying therapy-treated and -untreated people with multiple sclerosis in Germany: a claims data analysis from 2017 to 2022.Frontiers in neurology · 2025Article
- Analyses of Basal and Squamous Cell Carcinoma Reported as an Adverse Drug Reaction and Comparison with Cases from the Cancer Registry from Germany.Drugs in R&D · 2023Article
- The influence of the COVID-19 pandemic on the prescription of multiple sclerosis medication in Germany.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023Article
- Pregestational neurological disorders among women of childbearing age-Nationwide data from a 13-year period in Hungary.PloS one · 2022Article
- Article
- Real-World Treatment of Patients with Multiple Sclerosis per MS Subtype and Associated Healthcare Resource Use: An Analysis Based on 13,333 Patients in Germany.Neurology and therapy · 2020Article
- Multiple Sclerosis in the Campania Region (South Italy): Algorithm Validation and 2015-2017 Prevalence.International journal of environmental research and public health · 2020Article
- Article
- Article
- The Administrative Prevalence of Multiple Sclerosis in Greece on the Basis of a Nationwide Prescription Database.Frontiers in neurology · 2020Article
- Multi-drug use among patients with multiple sclerosis: A cross-sectional study of associations to clinicodemographic factors.Scientific reports · 2019Article
- Validation of an algorithm for identifying MS cases in administrative health claims datasets.Neurology · 2019Article
- Prevalence of multiple sclerosis in an urban population of Sivas province in TurkeyTurkish journal of medical sciences · 2019Article
- Acceptance of Mobile Health Apps for Disease Management Among People With Multiple Sclerosis: Web-Based Survey Study.JMIR formative research · 2018Article
- A Systematic Assessment of Prevalence, Incidence and Regional Distribution of Multiple Sclerosis in Bavaria From 2006 to 2015.Frontiers in neurology · 2018Article
- Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance data.Journal of neurology · 2017Article
- Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment.BMC neurology · 2017Article
- Health care resource utilization before and after natalizumab initiation among patients with multiple sclerosis in Germany.ClinicoEconomics and outcomes research : CEOR · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHealthcare-utilization data for multiple sclerosis (MS) are scarce in Germany. The Purpose of the study was to analyse administrative prevalence of MS, medication use and type of specialists involved in MS treatment in the outpatient setting in Bavaria.
methodsPseudonymized claims data from Bavarian Statutory Health Insurance (SHI)-accredited physicians were used. Administrative prevalence of MS was defined as having ≥1 MS diagnosis (International Classification of Diseases, 10th edition, code G35) documented by a neurologist or psychiatrist, or ≥1 prescription for disease-modifying drugs (DMDs)). The administrative prevalence calculated for Bavaria was projected to Germany. DMD prescription and involvement of different specialities in health care service for MS patients was analysed.
resultsAdministrative prevalence of MS in Bavaria increased from 0.123% to 0.175% of insured persons between 2005 and 2009; when projected, this yielded ~102,000-143,000 patients with MS in the German population. The percentage of patients receiving ≥1 DMD prescription increased from 45.5% to 50.5%. Patients with MS were mainly treated by neurologists in the ambulatory care setting.
conclusionsThese results provide important information on the administrative prevalence of MS in Bavaria and on healthcare provision for patients, which is relevant for resource planning in the healthcare sector.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.